Aclarion, Inc. has established a commercial agreement with Weill Cornell Medicine to bring its Nociscan technology to Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. The agreement involves integrating Nociscan into a clinical trial entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease," conducted under IRB Protocol No. 22-06024915. This trial, led by Principal Investigator Jaspal Ricky Singh, MD, aims to investigate whether the dose and quantity of BMAC used for treating osteoarthritis and degenerative disc disease affects patient-reported functional outcomes and pain.
The collaboration represents a significant advancement in applying artificial intelligence to chronic low back pain management, a condition affecting approximately 266 million people worldwide according to Global Spine Journal research. Nociscan is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine using biomarkers and proprietary augmented intelligence algorithms. A subset of spine patients in the trial, selected through Dr. Singh's clinical evaluation, will be eligible for Nociscan assessment as part of their comprehensive treatment approach.
Dr. Singh, who serves as Vice Chair and Director of Interventional Spine at Weill Cornell Medicine, emphasized that his team's multidisciplinary approach to treating spinal disorders includes physical therapy and various interventional techniques. "Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan," he stated. The technology objectively quantifies chemical biomarkers demonstrated to be associated with disc pain, providing critical insights into pain location when used alongside other diagnostic tools.
For business and technology leaders, this partnership demonstrates how healthcare technology companies are forming strategic alliances with academic medical centers to validate and expand clinical applications of AI-driven diagnostic platforms. The integration of Nociscan into Weill Cornell's research protocol could accelerate adoption of precision medicine approaches in spine care, potentially creating new standards for diagnosing and treating chronic low back pain. The commercial agreement also represents a revenue expansion opportunity for Aclarion as it moves beyond standalone diagnostic applications into integrated research partnerships.
The Nociscan platform operates through a cloud connection that receives magnetic resonance spectroscopy data from MRI machines, then uses proprietary signal processing techniques to extract and quantify pain-associated biomarkers. This data feeds into proprietary algorithms that indicate whether a disc may be a pain source. According to company information, Nociscan improves pain and function outcomes when all Nociscan-positive discs receive appropriate treatment. For more information about Aclarion's technology, visit https://www.aclarion.com.
This collaboration between a commercial-stage healthcare technology company and a leading academic medical center highlights the growing convergence of AI, biomarker analysis, and clinical research in addressing widespread healthcare challenges. The trial outcomes could influence treatment protocols for degenerative spine conditions and validate the role of AI-enhanced diagnostics in optimizing therapeutic interventions. For investors and industry observers, such partnerships signal maturation in the medical AI sector, where technology platforms are increasingly integrated into established clinical research frameworks at prestigious institutions.
